Sign up to watch this video
Free access to all Sound Bites content
Dr. Amer Zeidan reviews the data in luspatercept for lower-risk MDS including outcomes and OS (Video 2/3)
Published May 20, 2026
Medical Professional
COMMANDS Outcomes
Related Videos
Dr. Laura van ‘t Veer discusses baseline ctDNA as a predictive marker in neoadjuvant breast cancer (Video 1/3)
Laura van 't Veer, PhD
Dr. Arnab Basu reviews ctDNA risk status as a predictor of recurrence in bladder cancer (Video 2/3)
Arnab Basu, MD
Dr. Arnab Basu discusses ctDNA as a predictive marker in bladder cancer (Video 1/3)
Arnab Basu, MD
Dr. Manali Kamdar describes best practices and impact of timing for CAR-T utilization in patients with LBCL (Video 3/3)
Manali Kamdar, MD
Dr. Edgardo Santos describes the management of patients receiving SQ amivantamab-based regimens (Video 3/3)
Edgardo Santos, MD
Dr. Amer Zeidan describes the patient management with luspatercept including RS negative and EPO <200 (Video 3/3)
Amer Zeidan, MD
IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2025 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.